D. Western Therapeutics Institute, Inc. (TYO:4576)
47.00
-1.00 (-2.08%)
Nov 18, 2026, 11:05 AM JST
TYO:4576 Revenue
D. Western Therapeutics Institute had revenue of 18.00M JPY in the quarter ending September 30, 2026, a decrease of -85.47%. This brings the company's total for the last twelve months to 140.90M, down -66.43% year-over-year. In the year 2025, D. Western Therapeutics Institute had annual revenue of 387.00M, down -17.83%. That makes D. Western Therapeutics Institute the 43,834th largest company in the world by revenue and 3,863rd in Japan.
Revenue (ttm)
140.90M
Revenue Growth
-66.43%
P/S Ratio
19.62
Revenue / Employee
7.42M
Employees
19
Market Cap
2.71B
Revenue by Geography
- Netherlands 327.22M 84.4%
- Japan 60.08M 15.5%
- Others 319.00K 0.1%
Fiscal year ended Dec 31, 2025 See the full TYO:4576 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 387.00M | -84.00M | -17.83% |
| Dec 31, 2024 | 471.00M | 43.00M | 10.05% |
| Dec 31, 2023 | 428.00M | -20.00M | -4.46% |
| Dec 31, 2022 | 448.00M | 34.00M | 8.21% |
| Dec 31, 2021 | 414.00M | 59.00M | 16.62% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 14.02B |
| Kohjin Bio | 4.38B |
| Human Metabolome Technologies | 1.48B |
| PRISM BioLab Co.,LTD | 737.27M |
| SUSMED,Inc. | 679.00M |
| Kringle Pharma | 442.00M |
| Ribomic | 19.00M |
| Noile-Immune Biotech | 1.00M |